CD274 and neoplasm: Pardoll and his co-workers (6) showed that blocking co-inhibitory molecules from binding to ligands (blocking the PD-1/PD-L1 signaling pathway) can reverse the tumor immune microenvironment and enhance and maintain the endogenous anti-tumor effect, resulting in durable tumor control (7).